• 1
    Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434438.
  • 2
    Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 18441850.
  • 3
    Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003; 289: 30003004.
  • 4
    Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. HEPATOLOGY 2003; 37: 12021219.
  • 5
    Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114: 842845.
  • 6
    Berson A, De Beco V, Letteron P, Robin MA, Moreau C, El Kahwaji J, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998; 114: 764774.
  • 7
    Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147152.
  • 8
    Schoen FJ. Atherosclerosis. In: KumarV, AbbasAK, FaustoN, eds. Pathologic Basis of Disease. 7th ed. Philadelphia: Elsevier-Saunders, 2004: 516525.
  • 9
    Itabe H, Suzuki K, Tsukamoto Y, Komatsu R, Ueda M, Mori M, et al. Lysosomal accumulation of oxidized phosphatidylcholine-apolipoprotein B complex in macrophages: intracellular fate of oxidized low density lipoprotein. Biochim Biophys Acta 2000; 1487: 233245.
  • 10
    Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001; 103: 19551960.
  • 11
    Kayo S, Ohsawa M, Ehara S, Naruko T, Ikura Y, Hai E, et al. Oxidized low-density lipoprotein levels circulating in plasma and deposited in the tissues: comparison between Helicobacter pylori-associated gastritis and acute myocardial infarction. Am Heart J 2004; 148: 818825.
  • 12
    Guyton JR, Lenz ML, Mathews B, Hughes H, Karsan D, Selinger E, et al. Toxicity of oxidized low density lipoproteins for vascular smooth muscle cells and partial protection by antioxidants. Atherosclerosis 1995; 118: 237249.
  • 13
    Escargueil-Blanc I, Meilhac O, Pieraggi MT, Arnal JF, Salvayre R, Negre-Salvayre A. Oxidized LDLs induce massive apoptosis of cultured human endothelial cells through a calcium-dependent pathway. Prevention by aurintricarboxylic acid. Arterioscler Thromb Vasc Biol 1997; 17: 331339.
  • 14
    Wang GP, Deng ZD, Ni J, Qu ZL. Oxidized low density lipoprotein and very low density lipoprotein enhance expression of monocyte chemoattractant protein-1 in rabbit peritoneal exudate macrophages. Atherosclerosis 1997; 133: 3136.
  • 15
    Podrez EA, Poliakov E, Shen Z, Zhang R, Deng Y, Sun M, et al. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem 2002; 277: 3850338516.
  • 16
    Hazen SL, Chisolm GM. Oxidized phosphatidylcholines: pattern recognition ligands for multiple pathways of the innate immune response. Proc Natl Acad Sci U S A 2002; 99: 1251512517.
  • 17
    Itabe H, Takeshima E, Iwasaki H, Kimura J, Yoshida Y, Imanaka T, et al. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J Biol Chem 1994; 269: 1527415279.
  • 18
    Itabe H, Yamamoto H, Suzuki M, Kawai Y, Nakagawa Y, Suzuki A, et al. Oxidized phosphatidylcholines that modify proteins: analysis by monoclonal antibody against oxidized low density lipoprotein. J Biol Chem 1996; 271: 3320833217.
  • 19
    Yoshimi N, Ikura Y, Sugama Y, Kayo S, Ohsawa M, Yamamoto S, et al. Oxidized phosphatidylcholine in alveolar macrophages in idiopathic interstitial pneumonias. Lung 2005; 183: 109121.
  • 20
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 24672474.
    Direct Link:
  • 21
    Ikura Y, Morimoto H, Johmura H, Fukui M, Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol 1996; 91: 13671373.
  • 22
    Massarenti P, Biasi F, De Francesco A, Pauletto D, Rocca G, Silli B, et al. 4-Hydroxynonenal is markedly higher in patients on a standard long-term home parenteral nutrition. Free Radic Res 2004; 38: 7380.
  • 23
    Matsuo T, Ikura Y, Ohsawa M, Ogami M, Kayo S, Yoshimi N, et al. Mast cell chymase expression in Helicobacter pylori-associated gastritis. Histopathology 2003; 43: 538549.
  • 24
    Schneiderhan W, Schmid-Kotsas A, Zhao J, Grunert A, Nussler A, Weidenbach H, et al. Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis. HEPATOLOGY 2001; 34(Pt 1): 729737.
  • 25
    Fluiter K, Sattler W, De Beer MC, Connell PM, van der Westhuyzen DR, van Berkel TJ. Scavenger receptor BI mediates the selective uptake of oxidized cholesterol esters by rat liver. J Biol Chem 1999; 274: 88938899.
  • 26
    Ikura Y, Ohsawa M, Naruko T, Muraguchi T, Hirayama M, Suekane T, et al. Expression of the hepatic endothelin system in human cirrhotic livers. J Pathol 2004; 204: 304310.
  • 27
    Holley AE, Cheeseman KH. Measuring free radical reactions in vivo. Br Med Bull 1993; 49: 494505.
  • 28
    Pratico D. In vivo measurement of the redox state. Lipids 2001; 36( Suppl): S45S47.
  • 29
    White JS, Rees KR. The mechanism of action of 4-hydroxynonenal in cell injury. Chem Biol Interact 1984; 52: 233241.
  • 30
    Kuo CL, Vaz AD, Coon MJ. Metabolic activation of trans-4-hydroxy-2-nonenal, a toxic product of membrane lipid peroxidation and inhibitor of P450 cytochromes. J Biol Chem 1997; 272: 2261122616.
  • 31
    Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2002; 282: G193G199.
  • 32
    Ling W, Lougheed M, Suzuki H, Buchan A, Kodama T, Steinbrecher UP. Oxidized or acetylated low density lipoproteins are rapidly cleared by the liver in mice with disruption of the scavenger receptor class A type I/II gene. J Clin Invest 1997; 100: 244252.
  • 33
    Spickett CM, Rennie N, Winter H, Zambonin L, Landi L, Jerlich A, et al. Detection of phospholipid oxidation in oxidatively stressed cells by reversed-phase HPLC coupled with positive-ionization electrospray [correction of electroscopy] MS. Biochem J 2001; 355(Pt 2): 449457.
  • 34
    Tauchi-Sato K, Ozeki S, Houjou T, Taguchi R, Fujimoto T. The surface of lipid droplets is a phospholipid monolayer with a unique fatty acid composition. J Biol Chem 2002; 277: 4450744512.
  • 35
    Corradin SB, Buchmuller-Rouiller Y, Mauel J. Phagocytosis enhances murine macrophage activation by interferon-gamma and tumor necrosis factor-alpha. Eur J Immunol 1991; 21: 25532558.
  • 36
    Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, Bronk SF, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. HEPATOLOGY 2003; 38: 11881198.
  • 37
    Tadolini B, Cabrini L, Menna C, Pinna GG, Hakim G. Iron (III) stimulation of lipid hydroperoxide-dependent lipid peroxidation. Free Radic Res 1997; 27: 563576.
  • 38
    Noguchi N, Gotoh N, Niki E. Dynamics of the oxidation of low density lipoprotein induced by free radicals. Biochim Biophys Acta 1993; 1168: 348357.
  • 39
    Perez-Carreras M, Del Hoyo P, Martin MA, Rubio JC, Martin A, Castellano G, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. HEPATOLOGY 2003; 38: 9991007.
  • 40
    Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 430434.
  • 41
    Brunt EM. Alcoholic and nonalcoholic steatohepatitis. Clin Liver Dis 2002; 6: 399420, vii.
  • 42
    Aust SD, Morehouse LA, Thomas CE. Role of metals in oxygen radical reactions. J Free Radic Biol Med 1985; 1: 325
  • 43
    Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 2003; 30: 137144.
  • 44
    Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 11551163.
  • 45
    Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 2000; 28: 17171725.
  • 46
    Brown KE, Brunt EM, Heinecke JW. Immunohistochemical detection of myeloperoxidase and its oxidation products in Kupffer cells of human liver. Am J Pathol 2001; 159: 20812088.
  • 47
    Smiley PL, Stremler KE, Prescott SM, Zimmerman GA, McIntyre TM. Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J Biol Chem 1991; 266: 1110411110.
  • 48
    Casini A, Ceni E, Salzano R, Biondi P, Parola M, Galli A, et al. Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. HEPATOLOGY 1997; 25: 361367.
  • 49
    Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. HEPATOLOGY 2004; 39: 273278.